S&P 500   3,901.36 (+0.01%)
DOW   31,261.90 (+0.03%)
QQQ   288.68 (-0.31%)
AAPL   137.59 (+0.17%)
MSFT   252.56 (-0.23%)
FB   193.54 (+1.18%)
GOOGL   2,178.16 (-1.34%)
AMZN   2,151.82 (+0.25%)
TSLA   663.90 (-6.42%)
NVDA   166.94 (-2.51%)
BABA   86.79 (-1.03%)
NIO   16.44 (-1.32%)
AMD   93.50 (-3.28%)
CGC   5.52 (-5.96%)
MU   68.90 (-0.72%)
T   20.40 (+0.94%)
GE   75.25 (-0.65%)
F   12.50 (-2.72%)
DIS   102.42 (-0.70%)
AMC   12.03 (-8.03%)
PFE   52.47 (+3.59%)
PYPL   80.54 (-0.91%)
NFLX   186.35 (+1.56%)
S&P 500   3,901.36 (+0.01%)
DOW   31,261.90 (+0.03%)
QQQ   288.68 (-0.31%)
AAPL   137.59 (+0.17%)
MSFT   252.56 (-0.23%)
FB   193.54 (+1.18%)
GOOGL   2,178.16 (-1.34%)
AMZN   2,151.82 (+0.25%)
TSLA   663.90 (-6.42%)
NVDA   166.94 (-2.51%)
BABA   86.79 (-1.03%)
NIO   16.44 (-1.32%)
AMD   93.50 (-3.28%)
CGC   5.52 (-5.96%)
MU   68.90 (-0.72%)
T   20.40 (+0.94%)
GE   75.25 (-0.65%)
F   12.50 (-2.72%)
DIS   102.42 (-0.70%)
AMC   12.03 (-8.03%)
PFE   52.47 (+3.59%)
PYPL   80.54 (-0.91%)
NFLX   186.35 (+1.56%)
S&P 500   3,901.36 (+0.01%)
DOW   31,261.90 (+0.03%)
QQQ   288.68 (-0.31%)
AAPL   137.59 (+0.17%)
MSFT   252.56 (-0.23%)
FB   193.54 (+1.18%)
GOOGL   2,178.16 (-1.34%)
AMZN   2,151.82 (+0.25%)
TSLA   663.90 (-6.42%)
NVDA   166.94 (-2.51%)
BABA   86.79 (-1.03%)
NIO   16.44 (-1.32%)
AMD   93.50 (-3.28%)
CGC   5.52 (-5.96%)
MU   68.90 (-0.72%)
T   20.40 (+0.94%)
GE   75.25 (-0.65%)
F   12.50 (-2.72%)
DIS   102.42 (-0.70%)
AMC   12.03 (-8.03%)
PFE   52.47 (+3.59%)
PYPL   80.54 (-0.91%)
NFLX   186.35 (+1.56%)
S&P 500   3,901.36 (+0.01%)
DOW   31,261.90 (+0.03%)
QQQ   288.68 (-0.31%)
AAPL   137.59 (+0.17%)
MSFT   252.56 (-0.23%)
FB   193.54 (+1.18%)
GOOGL   2,178.16 (-1.34%)
AMZN   2,151.82 (+0.25%)
TSLA   663.90 (-6.42%)
NVDA   166.94 (-2.51%)
BABA   86.79 (-1.03%)
NIO   16.44 (-1.32%)
AMD   93.50 (-3.28%)
CGC   5.52 (-5.96%)
MU   68.90 (-0.72%)
T   20.40 (+0.94%)
GE   75.25 (-0.65%)
F   12.50 (-2.72%)
DIS   102.42 (-0.70%)
AMC   12.03 (-8.03%)
PFE   52.47 (+3.59%)
PYPL   80.54 (-0.91%)
NFLX   186.35 (+1.56%)
NASDAQ:ACAD

ACADIA Pharmaceuticals (ACAD) Stock Forecast, Price & News

$17.11
+0.28 (+1.66%)
(As of 05/20/2022 12:00 AM ET)
Add
Compare
Today's Range
$16.26
$17.21
50-Day Range
$15.29
$27.22
52-Week Range
$15.16
$28.06
Volume
1.31 million shs
Average Volume
1.55 million shs
Market Capitalization
$2.76 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.67
30 days | 90 days | 365 days | Advanced Chart
Receive ACAD News and Ratings via Email

Sign-up to receive the latest news and ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ACADIA Pharmaceuticals logo

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ACAD
Employees
514
Year Founded
N/A

Sales & Book Value

Annual Sales
$484.14 million
Book Value
$2.76 per share

Profitability

Net Income
$-167.87 million
Pretax Margin
-43.33%

Debt

Price-To-Earnings

Miscellaneous

Free Float
115,422,000
Market Cap
$2.76 billion
Optionable
Optionable

Company Calendar

Last Earnings
5/04/2022
Today
5/20/2022
Next Earnings (Estimated)
8/03/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.81 out of 5 stars

Medical Sector

33rd out of 1,420 stocks

Pharmaceutical Preparations Industry

10th out of 679 stocks

Analyst Opinion: 4.3Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.6 5 -4 -3 -2 -1 -













ACADIA Pharmaceuticals (NASDAQ:ACAD) Frequently Asked Questions

Is ACADIA Pharmaceuticals a buy right now?

17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last twelve months. There are currently 8 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ACADIA Pharmaceuticals stock.
View analyst ratings for ACADIA Pharmaceuticals
or view top-rated stocks.

Are investors shorting ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals saw a increase in short interest in April. As of April 30th, there was short interest totaling 12,000,000 shares, an increase of 48.0% from the April 15th total of 8,110,000 shares. Based on an average trading volume of 1,570,000 shares, the short-interest ratio is presently 7.6 days. Currently, 7.5% of the company's shares are short sold.
View ACADIA Pharmaceuticals' Short Interest
.

When is ACADIA Pharmaceuticals' next earnings date?

ACADIA Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for ACADIA Pharmaceuticals
.

How were ACADIA Pharmaceuticals' earnings last quarter?

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) posted its quarterly earnings results on Wednesday, May, 4th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, topping analysts' consensus estimates of ($0.60) by $0.27. The biopharmaceutical company had revenue of $115.47 million for the quarter, compared to analysts' expectations of $122.22 million. ACADIA Pharmaceuticals had a negative net margin of 43.50% and a negative trailing twelve-month return on equity of 40.52%. The business's revenue was up 8.4% on a year-over-year basis. During the same period in the previous year, the company posted ($0.42) EPS.
View ACADIA Pharmaceuticals' earnings history
.

What guidance has ACADIA Pharmaceuticals issued on next quarter's earnings?

ACADIA Pharmaceuticals issued an update on its FY 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $510.00 million-$560.00 million, compared to the consensus revenue estimate of $540.68 million.

What price target have analysts set for ACAD?

17 brokers have issued 1 year target prices for ACADIA Pharmaceuticals' shares. Their forecasts range from $23.00 to $37.00. On average, they anticipate ACADIA Pharmaceuticals' stock price to reach $29.45 in the next twelve months. This suggests a possible upside of 72.1% from the stock's current price.
View analysts' price targets for ACADIA Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are ACADIA Pharmaceuticals' key executives?
ACADIA Pharmaceuticals' management team includes the following people:
What is Steve Davis' approval rating as ACADIA Pharmaceuticals' CEO?

8 employees have rated ACADIA Pharmaceuticals CEO Steve Davis on Glassdoor.com. Steve Davis has an approval rating of 88% among ACADIA Pharmaceuticals' employees.

What other stocks do shareholders of ACADIA Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ACADIA Pharmaceuticals investors own include Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Sarepta Therapeutics (SRPT), Pfizer (PFE), Tesla (TSLA), Alibaba Group (BABA), Amarin (AMRN), Advanced Micro Devices (AMD) and Exelixis (EXEL).

What is ACADIA Pharmaceuticals' stock symbol?

ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD."

Who are ACADIA Pharmaceuticals' major shareholders?

ACADIA Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (7.79%), BlackRock Inc. (6.18%), State Street Corp (3.13%), First Trust Advisors LP (1.44%), JPMorgan Chase & Co. (1.43%) and Palo Alto Investors LP (1.39%). Company insiders that own ACADIA Pharmaceuticals stock include Austin D Kim, Austin D Kim, Brendan Teehan, Elena Ridloff, James Kihara, Michael J Yang, Srdjan R Stankovic, Srdjan R Stankovic and Stephen Davis.
View institutional ownership trends for ACADIA Pharmaceuticals
.

Which major investors are selling ACADIA Pharmaceuticals stock?

ACAD stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Federated Hermes Inc., Frontier Capital Management Co. LLC, UBS Group AG, BlackRock Inc., Palo Alto Investors LP, Goldman Sachs Group Inc., and Jane Street Group LLC. Company insiders that have sold ACADIA Pharmaceuticals company stock in the last year include Austin D Kim, Brendan Teehan, James Kihara, Srdjan R Stankovic, and Stephen Davis.
View insider buying and selling activity for ACADIA Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying ACADIA Pharmaceuticals stock?

ACAD stock was bought by a variety of institutional investors in the last quarter, including Fairmount Funds Management LLC, Invesco Ltd., Vanguard Group Inc., Sessa Capital IM L.P., State Street Corp, JPMorgan Chase & Co., The Manufacturers Life Insurance Company , and Panagora Asset Management Inc..
View insider buying and selling activity for ACADIA Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of ACADIA Pharmaceuticals?

Shares of ACAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ACADIA Pharmaceuticals' stock price today?

One share of ACAD stock can currently be purchased for approximately $17.11.

How much money does ACADIA Pharmaceuticals make?

ACADIA Pharmaceuticals has a market capitalization of $2.76 billion and generates $484.14 million in revenue each year. The biopharmaceutical company earns $-167.87 million in net income (profit) each year or ($1.330010) on an earnings per share basis.

How many employees does ACADIA Pharmaceuticals have?

ACADIA Pharmaceuticals employs 514 workers across the globe.

What is ACADIA Pharmaceuticals' official website?

The official website for ACADIA Pharmaceuticals is www.acadia-pharm.com.

How can I contact ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals' mailing address is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. The biopharmaceutical company can be reached via phone at (858) 558-2871, via email at [email protected], or via fax at 858-558-2872.

This page was last updated on 5/20/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.